Course info
Sections
General
0 activities
652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III
0 activities
Patient derived amyloidogenic light chain triggers cardiovascular toxicity In Vivo and reveals ICAM 1 as a novel potential biomarker in patients with AL amyloidosis
1 activities
Laboratory characteristics of monoclonal gammopathy of undetermined significance MGUS in a diverse sample from three large cancer epidemiology cohorts
1 activities
Circulating immune profile in patients with amyloidosis
1 activities
Effectiveness of second line therapies following upfront daratumumab plus bortezomib cyclophosphamide and dexamethasone A new benchmark
1 activities
Efficacy of venetoclax in the treatment of relapsed refractory light chain amyloidosis
1 activities
Mass spectrometry based screening for monoclonal gammopathy in individuals undergoing physical examinations Analyses of consecutive 15 068 cases in China
1 activities
High neutrophil to lymphocyte ratio does not predict MGUS to myeloma progression but is associated with worse survival as a marker of global inflammation
1 activities
Disease characteristics treatment patterns and outcomes of AL amyloidosis patients with high risk FISH cytogenetics
1 activities
Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab based frontline therapy
1 activities
Cyclin D1 immunostaining as a diagnostic surrogate for the t 11 14 translocation in AL amyloidosis
1 activities
Prognostic value of mayo 2012 vs european‑modified mayo 2004 staging in AL amyloidosis patients with discordant stage classifications
1 activities
Nationwide real world outcomes of POEMS syndrome Long term impact of ASCT maintenance therapy and relapse strategies in Japan
1 activities
The use of MYD88 and IGH PCR in the diagnosis and follow up of Βing neel syndrome
1 activities
13